Evolocumab in STEMI

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 166 participants.

Also called NCT06081803

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 166 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06081803
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06081803. Randomized; single masking; primary purpose treatment. Start 2020-12-05 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evolocumab in STEMI
Acronym
EVO-STEMI
Condition
ST Elevation Myocardial Infarction
Intervention (Drug)
Repatha®
Lead sponsor
Sejong General Hospital (class: other)
Collaborator
Samsung Medical Center (class: other)
Collaborator
National Health Insurance Service Ilsan Hospital (class: other)
Collaborator
Chonnam National University Hospital (class: other)
Collaborator
Daegu Catholic University Medical Center (class: other)
Collaborator
Catholic University of Korea Eunpyeong St. Mary's Hospital (class: not stated)

Record details

Record id
cardio:ct-nct06081803
Content hash
a67157b341fd8aef018d244faa0fe52cb7c3b2ce62d3a7ab6085417b9cdef41a